Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Background: According to the results of a number of phase 3 randomized studies, sorafenib is the only approved systemic therapy for advanced HCC; however the issue of high economic cost remains challenging; thus we have conducted this retrospective analysis of our HCC patients treated with sorafenib...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2014-03-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036213000903 |